Literature DB >> 17215851

Clinical significance of TP53 mutation in myeloma.

W J Chng, T Price-Troska, N Gonzalez-Paz, S Van Wier, S Jacobus, E Blood, K Henderson, M Oken, B Van Ness, P Greipp, S V Rajkumar, R Fonseca.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17215851     DOI： 10.1038/sj.leu.2404524

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  58 in total

1.  Anaplastic plasmacytoma of mouse--establishing parallels between subtypes of mouse and human plasma cell neoplasia.

Authors:  Daphne de Jong; Siegfried Janz
Journal:  J Pathol       Date:  2010-07       Impact factor: 7.996

2.  The novel autophagy inhibitor elaiophylin exerts antitumor activity against multiple myeloma with mutant TP53 in part through endoplasmic reticulum stress-induced apoptosis.

Authors:  Gaoxiang Wang; Pan Zhou; Xing Chen; Lei Zhao; Jiaqi Tan; Yang Yang; Yong Fang; Jianfeng Zhou
Journal:  Cancer Biol Ther       Date:  2017-07-18       Impact factor: 4.742

3.  Clinical and biological significance of RAS mutations in multiple myeloma.

Authors:  W J Chng; N Gonzalez-Paz; T Price-Troska; S Jacobus; S V Rajkumar; M M Oken; R A Kyle; K J Henderson; S Van Wier; P Greipp; B Van Ness; R Fonseca
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

4.  Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.

Authors:  Morihiko Sagawa; Hiroto Ohguchi; Takeshi Harada; Mehmet K Samur; Yu-Tzu Tai; Nikhil C Munshi; Masahiro Kizaki; Teru Hideshima; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2017-04-25       Impact factor: 12.531

5.  Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.

Authors:  Manujendra N Saha; Hua Jiang; Hong Chang
Journal:  Cancer Biol Ther       Date:  2010-10-01       Impact factor: 4.742

6.  RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.

Authors:  Hans C Lee; Hua Wang; Veerabhadran Baladandayuthapani; Heather Lin; Jin He; Richard J Jones; Isere Kuiatse; Dongmin Gu; Zhiqiang Wang; Wencai Ma; John Lim; Sean O'Brien; Jonathan Keats; Jing Yang; Richard E Davis; Robert Z Orlowski
Journal:  Br J Haematol       Date:  2017-04       Impact factor: 6.998

7.  Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.

Authors:  Maria T Di Martino; Emanuela Leone; Nicola Amodio; Umberto Foresta; Marta Lionetti; Maria R Pitari; Maria E Gallo Cantafio; Annamaria Gullà; Francesco Conforti; Eugenio Morelli; Vera Tomaino; Marco Rossi; Massimo Negrini; Manlio Ferrarini; Michele Caraglia; Masood A Shammas; Nikhil C Munshi; Kenneth C Anderson; Antonino Neri; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Clin Cancer Res       Date:  2012-10-03       Impact factor: 12.531

Review 8.  Genetic events in the pathogenesis of multiple myeloma.

Authors:  W J Chng; O Glebov; P L Bergsagel; W M Kuehl
Journal:  Best Pract Res Clin Haematol       Date:  2007-12       Impact factor: 3.020

9.  Mutational analysis of TP53 gene in Tunisian familial hematological malignancies and sporadic acute leukemia cases.

Authors:  Walid Sabri Hamadou; Sawsen Besbes; Violaine Bourdon; Yosra Ben Youssef; Mohamed Adnène Laatiri; Testsuro Noguchi; Abderrahim Khélif; Hagay Sobol; Zohra Soua
Journal:  Fam Cancer       Date:  2017-01       Impact factor: 2.375

10.  Genetic aberrations and survival in plasma cell leukemia.

Authors:  R E Tiedemann; N Gonzalez-Paz; R A Kyle; R Santana-Davila; T Price-Troska; S A Van Wier; W J Chng; R P Ketterling; M A Gertz; K Henderson; P R Greipp; A Dispenzieri; M Q Lacy; S V Rajkumar; P L Bergsagel; A K Stewart; R Fonseca
Journal:  Leukemia       Date:  2008-01-24       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.